Skip to content
Announcement:

The results of a recent collaboration between Sanofi, GSK, Lilly, Vesalius Therapeutics, Leiden University, Heidelberg University, ElmorePathology and Newcells aimed at enhancing safety assessments has just been published. Find out how rat kidney gene co-expression networks has enabled biomarker identification and human translation for renal safety assessments.

WHY WE DO IT

Our purpose is to bridge the gap between scientific discovery and patients. We make a difference by providing better predictions of clinical outcomes.

Don't miss out on our latest innovations: follow us on Linkedin

Author

Newcells Biotech

Published

24th April, 2019

Categories

Update

Get our latest updates straight to your inbox

Book a Call